secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2021-11-16T23:59:59+00:00
Accession:  0001564590-21-057143
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea Biotherapeutics appoints Hunter Smith to board of directors and audit committee
--------------------------------------------------------------------------------

- Hunter Smith appointed as Class I director and Audit Committee member effective November 12, 2021.
- Smith is CFO of Rhythm Pharmaceuticals (since July 2017) and previously VP Finance at Celgene.
- Receives pro rata director retainer ($40,000 annual) and audit committee retainer ($7,500 annual).
- Granted option to purchase 60,000 shares at closing price on November 12, 2021, vesting monthly over three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000156459021057143/0001564590-21-057143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000156459021057143/agle-8k_20211112.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-057143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer